GOLDENWELL BIOTECH, INC.

Goldenwell Biotech, Inc. develops nutraceutical and dietary supplement products. Its offerings are organized into polypeptide freeze-dried powders and solid tablet formulations. The polypeptide products include bovine cardiac vascular active peptides, three-dimensional active collagen peptides designed for bodily absorption, and type II cartilage collagen supplements. The solid tablet line features Se Plus, an antioxidant and organoselenium compound, and Sugar Master, a cryogenic plant extract supplement. The company targets consumers seeking nutritional support, particularly middle-aged and elderly individuals, people exposed to environmental pollutants, and individuals experiencing selenium deficiencies.

The enterprise is headquartered in Solon, Ohio, maintaining an office address used exclusively for mail delivery without on-site operations. The company does not own physical real estate, and its three non-employee officers operate remotely. Its proprietary technology licenses encompass worldwide territories with the exception of China. Goldenwell Biotech has not established production facilities or retail locations, as it remains in an early stage without operational manufacturing workshops.

Summary of the business section of Goldenwell Biotech's latest annual report, written by StockData.